Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Evidence of antitumor efficacy for SRL-712 and IL-2 in advanced melanoma

Sep. 22, 2003

Acceptable safety profile described for NBI-3001 in recurrent malignant glioma

Sep. 19, 2003

Aastrom receives SBIR grant for dendritic cell vaccine research

Sep. 18, 2003

Enrollment completed in phase I breast cancer trial for HER-2 AutoVac Protein vaccine

Sep. 15, 2003

Phase I/II trial approved to evaluate Collidem in colorectal cancer

Sep. 12, 2003

Antisoma acquires Cytogen's R-1549 royalty rights

Sep. 12, 2003

Private equity financing to advance development of Panvac-VF and Prostvac-VF

Sep. 12, 2003

New phase II trial evaluates MDX-010 for metastatic breast cancer

Sep. 10, 2003

Provenge receives fast track designation

Sep. 8, 2003

Partial clinical hold on phase III Oncophage trials

Sep. 5, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 22, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 22, 2025.
In 2025, science’s biggest story was political
BioWorld
In 2025, science saw its breakthroughs, which BioWorld will be covering as part of our end-of-the-year wrap-up. But the biggest science story of 2025 is not about...
FDA says yes to Cytokinetics’ aficamten, now Myqorzo, in oHCM
BioWorld
Cytokinetics Inc. scored U.S. FDA marketing clearance Dec. 19 for Myqorzo (aficamten) 5-mg, 10-mg, 15-mg, and 20-mg tablets to improve functional capacity and...
Conjugating ferrocene to GPX4 inhibitors to promote ferroptosis
BioWorld Science
Small molecules that induce iron-dependent oxidative cell death known as ferroptosis can be effective against tumors that are resistant to other therapies....